ca 125 antigen

Summary

Summary: Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.

Top Publications

  1. ncbi Epithelial ovarian tumors and CA125 in premenarchal girls
    Z Stankovic
    Department of Pediatric and Adolescent Gynecology, Surgery and Pathology, Mother and Child Health Institute of Serbia
    Eur J Gynaecol Oncol 27:597-9. 2006
  2. ncbi Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:327-31. 2008
  3. ncbi Cancer of the ovary
    Stephen A Cannistra
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 351:2519-29. 2004
  4. ncbi Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology
    S C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 93:1458-64. 2001
  5. ncbi Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery
    Nathalie Scholler
    Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 1024, USA
    Cancer Lett 247:130-6. 2007
  6. ncbi Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer
    Brian C Cooper
    Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Clin Cancer Res 8:3193-7. 2002
  7. ncbi Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
    Armin Rump
    Institute of Molecular and Cellular Biosciences, University of Tokyo, Bunkyo ku, Tokyo 113 0032, Japan
    J Biol Chem 279:9190-8. 2004
  8. ncbi Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer
    M Varras
    University General Hospital Attikon, Athens, Greece
    Clin Exp Obstet Gynecol 31:85-98. 2004
  9. ncbi Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer
    Anna E Lokshin
    University of Pittsburgh Cancer Institute, Hillman Cancer Center, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Gynecol Oncol 102:244-51. 2006
  10. ncbi Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125
    Manish S Patankar
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, 600 Highland Avenue, H4 657 CSC, Madison, WI 53792 6188, USA
    Gynecol Oncol 99:704-13. 2005

Detail Information

Publications191 found, 100 shown here

  1. ncbi Epithelial ovarian tumors and CA125 in premenarchal girls
    Z Stankovic
    Department of Pediatric and Adolescent Gynecology, Surgery and Pathology, Mother and Child Health Institute of Serbia
    Eur J Gynaecol Oncol 27:597-9. 2006
    ..CA125 is a tumor marker with low sensitivity and specificity for detection of epithelial ovarian malignancy in this age group...
  2. ncbi Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:327-31. 2008
    ..The aim of this retrospective study is to analyze the prognostic value of the CA-125 nadir after the completion of an optimal primary treatment...
  3. ncbi Cancer of the ovary
    Stephen A Cannistra
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 351:2519-29. 2004
  4. ncbi Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology
    S C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 93:1458-64. 2001
    ..We used microarray technology to identify overexpressed genes for secretory proteins as potential serum biomarkers and selected prostasin, a serine protease normally secreted by the prostate gland, for further study...
  5. ncbi Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery
    Nathalie Scholler
    Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 1024, USA
    Cancer Lett 247:130-6. 2007
    ..We finally demonstrated that a mesothelin chimeric protein and anti-CA125 antibodies block CA125/mesothelin-dependent cell attachment...
  6. ncbi Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer
    Brian C Cooper
    Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Clin Cancer Res 8:3193-7. 2002
    ..004) were significant. CONCLUSIONS: Preoperative VEGF levels may be useful in differentiating benign adnexal masses from malignancy. Preoperative VEGF levels >380 pg/ml are an independent risk factor for death because of disease...
  7. ncbi Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
    Armin Rump
    Institute of Molecular and Cellular Biosciences, University of Tokyo, Bunkyo ku, Tokyo 113 0032, Japan
    J Biol Chem 279:9190-8. 2004
    ....
  8. ncbi Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer
    M Varras
    University General Hospital Attikon, Athens, Greece
    Clin Exp Obstet Gynecol 31:85-98. 2004
    ..Pelvic ultrasonography as a screening method for the early detetection of ovarian cancer should be probably limited to those women who are at increased risk for development of ovarian cancer and not in the general population...
  9. ncbi Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer
    Anna E Lokshin
    University of Pittsburgh Cancer Institute, Hillman Cancer Center, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Gynecol Oncol 102:244-51. 2006
    ..The objective of this study was, therefore, to evaluate the potential importance of circulating anti-IL-8 antibody as ovarian cancer biomarker...
  10. ncbi Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125
    Manish S Patankar
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, 600 Highland Avenue, H4 657 CSC, Madison, WI 53792 6188, USA
    Gynecol Oncol 99:704-13. 2005
    ..CA125 expresses specific oligosaccharides that can inhibit the cytotoxicity of human natural killer (NK) cells. The current study was undertaken to determine the ability of CA125 to modulate NK cell-mediated cytotoxicity...
  11. ncbi Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)
    Jennifer A Belisle
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI 53792, USA
    Immunology 122:418-29. 2007
    ..Similar to EOC, MUC16 in early pregnancy also binds to NK cells suggesting shared mechanisms of NK cell suppression in feto-maternal tolerance and immune evasion by ovarian cancers...
  12. ncbi Potential markers that complement expression of CA125 in epithelial ovarian cancer
    Daniel G Rosen
    Department of Pathology, University of Texas M.D. Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 99:267-77. 2005
    ..Several markers exhibited more intense expression in cancers than in normal organs. Further investigation is needed to demonstrate complementary expression of markers in serum...
  13. ncbi Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    Usha Menon
    Gynaecological Oncology, University College London Elizabeth Garrett Anderson Institute for Women s Health, London, UK
    Lancet Oncol 10:327-40. 2009
    ..This report summarises the outcome of the prevalence (initial) screen in UKCTOCS...
  14. ncbi Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma
    Osnat Bairey
    Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
    Leuk Lymphoma 44:1733-8. 2003
    ..In conclusion, CA 125 is not only a reliable marker for staging and assessing tumor activity in NHL, elevated levels are also predictive of decreased survival...
  15. ncbi Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer
    Elieser Gorelik
    Department of Pathology and Immunology, University of Pittsburg School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Cancer Epidemiol Biomarkers Prev 14:981-7. 2005
    ..5% sensitivity and 93.0% specificity. The presented data show that simultaneous testing of a panel of serum cytokines and CA-125 using LabMAP technology may present a promising approach for ovarian cancer detection...
  16. ncbi Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis
    Pompilio Faggiano
    Cattedra di Cardiologia, , Brescia, Italy
    J Am Coll Cardiol 41:1805-11. 2003
    ..Furthermore, fluctuations of CA125 serum levels over time may reflect changes induced by therapy. Therefore, measurements of CA 125 serum levels might be proposed for the serial assessment of CHF patients...
  17. ncbi The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma
    Fl Bădulescu
    Department of Oncology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, and Department of Pathology, Emergency County Hospital, Romania
    Rom J Morphol Embryol 46:329-34. 2005
    The purpose of this study is to compare the predicted value of the blood levels variations of CA 125 antigen and the imunohistochemical expression of CA 125, with imagistic criteria (The Response Evaluation Criteran in Solid Tumor--RECIST)..
  18. ncbi Ovarian cancer screening
    Nicole Urban
    Cancer Prevention Research Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, MP 900, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Hematol Oncol Clin North Am 17:989-1005, ix. 2003
    ..Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods...
  19. ncbi A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker
    Martin W McIntosh
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue MP 900, Seattle, WA 98109, USA
    Biostatistics 4:27-40. 2003
    ..Our method was specifically developed for use in screening for cancer with a new biomarker, but it is appropriate whenever the pre-clinical behavior of the disease and/or biomarker is uncertain...
  20. ncbi Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
    Jennifer A A Gubbels
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, USA
    Mol Cancer 5:50. 2006
    ..Here we have addressed this deficit and provide further evidence supporting the role of the MUC16-mesothelin interaction in facilitating cell-cell binding under conditions that mimic the peritoneal environment...
  21. ncbi The diagnostic value of PET/CT for primary ovarian cancer--a prospective study
    Signe Risum
    Dept of Oncology, 5073, The Finsen Center, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Gynecol Oncol 105:145-9. 2007
    ..To prospectively evaluate the diagnostic value of combined PET/CT in detecting a malignant tumor in patients with no previous cancer history, presenting with a pelvic mass...
  22. ncbi Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients
    Manabu Yamamoto
    Department of Surgery, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, 1 9 6 Senda machi, Hiroshima 730 8619, Japan
    J Cancer Res Clin Oncol 133:471-6. 2007
    ..We recently found an elevation in the pre-operative peritoneal lavage carcinoembryonic antigen (CEA) level to be associated with an earlier detection of recurrent peritoneal dissemination and a poor prognosis...
  23. ncbi CA-125 criteria for response evaluation in ovarian cancer
    S Sundar
    Gynecol Oncol 98:520-1. 2005
  24. ncbi New tumor markers: CA125 and beyond
    R C Bast
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 15:274-81. 2005
    ..In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer...
  25. ncbi Do levels of serum cancer antigen 125 and creatine kinase predict the outcome in pregnancies of unknown location?
    G Condous
    Early Pregnancy Unit, St George s Hospital Medical School, London, UK
    Hum Reprod 20:3348-54. 2005
    ..The aim of this study was to evaluate the role of maternal serum cancer antigen 125 (CA 125) and creatine kinase (CK) levels in predicting the outcome of pregnancies of unknown location (PUL)...
  26. ncbi Elevation of the tumor marker CA125 in right heart failure
    Boban Mathew
    Division of Cardiology, The Department of Internal Medicine, State University of New York, Buffalo, NY, USA
    South Med J 97:1013-4. 2004
    ..A case of elevated carbohydrate antigen 125 in isolated right heart failure due to atrial septal defect with preserved left ventricular function is reported...
  27. ncbi Screening for familial ovarian cancer: the need for well-designed prospective studies
    Ian Jacobs
    J Clin Oncol 23:5443-5. 2005
  28. ncbi Factors associated with cytoreducibility among women with ovarian carcinoma
    Gamal H Eltabbakh
    Lake Champlain Gynecologic Oncology, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Gynecol Oncol 95:377-83. 2004
    ..The aim of the current study is to investigate the clinical and molecular factors associated with cytoreduction among women with advanced stage epithelial ovarian carcinoma EOC...
  29. ncbi BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
    T Bjørge
    Department of Pathology, The Norwegian Radium Hospital, Oslo N 0310, Norway
    Br J Cancer 91:1829-34. 2004
    ..The sensitivity of using CA125 only as a screening test for ovarian cancer was low...
  30. ncbi Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer
    Zhen Zhang
    Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 64:5882-90. 2004
    ..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer...
  31. ncbi Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma
    Jamal Zidan
    Oncology Unit, Sieff Government Hospital, POB 1008, Safed, Israel
    Oncologist 9:417-21. 2004
    ..The aim of the current study is to evaluate CA125 levels in patients with NHL and to investigate the correlations between high CA125 level and other presenting features...
  32. ncbi The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 94:74-9. 2004
    ....
  33. ncbi CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Gynecol Cancer 15:679-91. 2005
    ..CA125 is the ovarian cancer marker against which new markers for this malignancy should be judged...
  34. ncbi Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics
    Riitta Antila
    Department of Obstetrics and Gynecology, University of Helsinki, PO Box 140, 00029 HUS, Helsinki, Finland
    Gynecol Oncol 101:97-101. 2006
    ..Size less than 9 cm, solid structure, absence of ascites and elevated serum CEA and TATI levels were typical features associated with secondary ovarian malignancies...
  35. ncbi Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
    Gordon J S Rustin
    Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    Clin Cancer Res 10:3919-26. 2004
  36. ncbi Receiver operator characteristics and diagnostic value of progesterone and CA-125 in the prediction of ectopic and abortive intrauterine gestations
    Ilias Katsikis
    Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Eur J Obstet Gynecol Reprod Biol 125:226-32. 2006
    ..CONCLUSION: The measurement of progesterone and CA-125 levels is useful in discriminating ectopic and intrauterine abortive from normal gestations...
  37. ncbi Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
    Gordon J S Rustin
    J Natl Cancer Inst 96:487-8. 2004
  38. ncbi Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125
    Nyet Kui Wong
    Department of Biological Sciences, Imperial College of Science, Technology and Medicine, London SW7 2AY, United Kingdom
    J Biol Chem 278:28619-34. 2003
    ..Immunotherapy directed against CA125 may attenuate these immunosuppressive effects, leading to the prolonged survival of patients with this extremely serious form of cancer...
  39. ncbi Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7
    Annechien J A Lambeck
    Department of Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Clin Cancer Res 13:2385-91. 2007
    ..To evaluate if serum cytokine levels could be used as diagnostic or prognostic markers in ovarian cancer...
  40. ncbi CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis
    Marianne Boivin
    Departement De Microbiologie et Infectiologie, Universite de Sherbrooke, 3001, 12ième Avenue Nord, Sherbrooke J1H 5N1, Canada
    Gynecol Oncol 115:407-13. 2009
    ..Little is known about the biological functions of CA125/MUC16 tumor antigen. Here, we examined the role of CA125/MUC16 in regulating the sensitivity of epithelial ovarian carcinoma (EOC) cells to different drugs...
  41. ncbi Ovarian cancer antigen CA 125 influences adhesion of human and mammalian cell lines in vitro
    R Gaetje
    Clinic of Frauenheilkunde and Geburtshilfe, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Exp Obstet Gynecol 29:34-6. 2002
    ..The results suggest that the ovarian cancer antigen CA 125 influences cell adhesion in vitro...
  42. ncbi Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study
    Omer Topalak
    Department of Internal Medicine, Dokuz Eylul University School of Medicine, 35330 Inciralti, Izmir, Turkey
    Gynecol Oncol 85:108-13. 2002
    ..The aim of this study is to investigate serum and fluid CA-125 levels in patients with different diseases...
  43. ncbi Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene
    Beatrice W T Yin
    Immunology Program, Sloan Kettering Institute, New York, NY 10021, USA
    Int J Cancer 98:737-40. 2002
    ..The cloning and expression of CA125 antigen opens the way to an understanding of its function in normal and malignant cells...
  44. ncbi Diagnostic markers for early detection of ovarian cancer
    Irene Visintin
    Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 14:1065-72. 2008
    ..In this study, we characterize and validate the combination of six serum biomarkers that discriminate between disease-free and ovarian cancer patients with high efficiency...
  45. ncbi The CA 125 gene: an extracellular superstructure dominated by repeat sequences
    T J O'Brien
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Tumour Biol 22:348-66. 2001
    ..Sequencing the gene provides us with the ability to initiate the quest to understand the biological function of CA 125...
  46. ncbi Release of membrane-associated mucins from ocular surface epithelia
    Timothy D Blalock
    Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA
    Invest Ophthalmol Vis Sci 49:1864-71. 2008
    ..Soluble forms of MAMs are detected in human tears, but the mechanisms of their release from the apical cells are unknown. The purpose of this study was to identify physiologic agents that induce ocular surface MAM release...
  47. ncbi The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Vladimir Nossov
    Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA 90095 1740, USA
    Am J Obstet Gynecol 199:215-23. 2008
    ..In this review, we hope to provide an overview of the early detection ovarian cancer from traditional methods to recent promises in the proteomics pipeline...
  48. ncbi Role of tumour markers in monitoring epithelial ovarian cancer
    T Meyer
    Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, UK
    Br J Cancer 82:1535-8. 2000
    ..Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present...
  49. ncbi Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16
    B W Yin
    Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biol Chem 276:27371-5. 2001
    ..Northern blotting showed that the level of MUC16 mRNA correlated with the expression of CA125 in a panel of cell lines. The molecular cloning of the CA125 antigen will lead to a better understanding of its role in ovarian cancer...
  50. ncbi Combining a symptoms index with CA 125 to improve detection of ovarian cancer
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer 113:484-9. 2008
    ....
  51. ncbi Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
    S Yamamoto
    Department of Gynecology and Obstetrics, Faculty of Medicine, Kyoto University, Japan
    Br J Cancer 76:1221-7. 1997
    ..Therefore, serum VEGF could be used as a marker for monitoring the clinical course of ovarian cancer patients...
  52. ncbi Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule
    K O Lloyd
    Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 71:842-50. 1997
    ..Further insight into the structure and function of the CA125 antigen will come from cloning the gene coding for the peptide backbone, and from more detailed carbohydrate structural analysis...
  53. ncbi Results from four rounds of ovarian cancer screening in a randomized trial
    Edward Partridge
    University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294, USA
    Obstet Gynecol 113:775-82. 2009
    ..To test whether annual screening with transvaginal ultrasonography and CA 125 reduces ovarian cancer mortality...
  54. ncbi Generating longitudinal screening algorithms using novel biomarkers for disease
    Martin W McIntosh
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 11:159-66. 2002
    ..The algorithm is particularly useful when screening with a new marker of which the behavior in the preclinical period is not well known...
  55. ncbi Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer
    Iris Simon
    diaDexus, Inc, 343 Oyster Point Blvd, South San Francisco, CA 94080, USA
    Gynecol Oncol 106:112-8. 2007
    ..In this study, we identified and evaluated three new serum biomarkers that may be used to improve detection of ovarian cancer...
  56. ncbi MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells
    Julia R Davies
    Mucosal Biology Group, Department of Experimental Medical Science, Lund University, BMC, C13, S 221 84 Lund, Sweden
    Int J Biochem Cell Biol 39:1943-54. 2007
    ....
  57. ncbi MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence
    Ilene K Gipson
    Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA
    Biol Reprod 78:134-42. 2008
    ..These data indicate that MUC16 is a membrane component of the nonreceptive luminal uterine surface, which prevents cell adhesion, and that its removal during uterodome formation facilitates adhesion of the trophoblast...
  58. ncbi Combining several screening tests: optimality of the risk score
    Martin W McIntosh
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
    Biometrics 58:657-64. 2002
    ..Moreover, our methods justify the development of clinical prediction scores based on binary regression...
  59. ncbi The cancer antigen CA125 represents a novel counter receptor for galectin-1
    Claudia Seelenmeyer
    Biochemie Zentrum Heidelberg, Im Neuenheimer Feld 328, 69120 Heidelberg, Germany
    J Cell Sci 116:1305-18. 2003
    ....
  60. ncbi The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure
    Timothy J O'Brien
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Ark 72205, USA
    Tumour Biol 23:154-69. 2002
    ..These additional data in association with our previous understanding of this molecule will provide the basis for our ability to understand the physiologic function of this molecule in biologic development and pathologic transformation...
  61. ncbi Use of CA-125 to assess response to new agents in ovarian cancer trials
    Gordon J S Rustin
    Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    J Clin Oncol 21:187s-193s. 2003
    ..These definitions already have been shown to be valuable in assessing efficacy of new agents but require further prospective evaluation...
  62. ncbi An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy
    Ping Yu Liu
    Southwest Oncology Group Statistical Center, Seattle, WA, USA
    J Clin Oncol 25:3615-20. 2007
    ..PATIENTS AND METHODS The EPD criterion was tested on Southwest Oncology Group trial 9701/Gynecologic Oncology Group trial 178 patients (n = 288) and compared with Gynecologic Cancer Intergroup criterion...
  63. ncbi Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment
    Lindsay Bergan
    Molecular Diagnositics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Lett 255:263-74. 2007
    ..Anti-mesothelin Bbs derived from high affinity yeast-display scFv detected both membrane-bound and soluble mesothelins and inhibited CA125/mesothelin-dependent cell attachment...
  64. ncbi Tissue AP-2gamma and Oct-3/4, and serum CA 125 as diagnostic and prognostic markers of malignant ovarian germ cell tumors
    Jonna Salonen
    Children s Hospital and Program for Women s Health, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    Tumour Biol 29:50-6. 2008
    ..Taken together, increased preoperative serum CA 125 levels indicate poor prognosis of MOGCTs. Tissue AP-2gamma and Oct-3/4 are associated with dysgerminomas and can thus be used as additional differential diagnostic tools in MOGCTs...
  65. ncbi Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer
    Hee Seung Kim
    Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Onkologie 31:315-20. 2008
    ..The aim of this study was to evaluate the prognostic value of the serum CA-125 level for complete responders after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy in advanced epithelial ovarian cancer...
  66. ncbi Glycomics analysis of serum: a potential new biomarker for ovarian cancer?
    G S Leiserowitz
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, UC Davis Medical Center, Sacramento, California, USA
    Int J Gynecol Cancer 18:470-5. 2008
    ..954 (95% CI: 0.896, 1.0) using the glycomics assay, which was superior to CA125 in discriminating between cases and controls. This preliminary study suggests that glycomics profiling may be useful for the detection of ovarian cancer...
  67. ncbi Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas
    Gerhard Oremek
    Department of Laboratory Medicine, Hospital of the Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Anticancer Res 27:1961-2. 2007
    ..The aim of this study was the investigation of the diagnostic value of the amino-terminal propeptide of type I collagen (P1NP) and the tumour markers, CA 15-3 and CA 125, in patients with breast and ovarian cancer...
  68. ncbi Analysis of metastatic ovarian tumors from extragenital primary sites
    Taner Turan
    Gynecologic Oncology Division, Ankara Etlik Maternity and Women s Health Teaching Hospital, Ankara, Turkey
    Tumori 92:491-5. 2006
    ..The aim of this study was to evaluate patients with metastatic ovarian tumors from extragenital primary sites...
  69. ncbi The use and understanding of CA125 as a tumor marker for ovarian cancer: a questionnaire-based survey
    E L Moss
    Academic Department of Obstetrics and Gynaecology, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom
    Int J Gynecol Cancer 18:439-45. 2008
    ..Substantial cost savings could be made by the introduction of clear protocol-driven ordering in an attempt to reduce the number of inappropriate tests performed...
  70. ncbi Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)
    Subhash C Chauhan
    Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198 5870, USA
    Mod Pathol 19:1386-94. 2006
    ....
  71. ncbi Ovarian cancer screening: a look at the evidence
    Margaret M Fields
    Clin J Oncol Nurs 10:77-81. 2006
    ..Ongoing clinical trials are assessing whether new tumor markers, including those generated by proteomic and genomic studies, will prove useful...
  72. ncbi Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125
    Ben Van Calster
    Department of Electrical Engineering, ESAT SISTA, Katholieke Universiteit Leuven, Belgium
    J Natl Cancer Inst 99:1706-14. 2007
    ..e., ovarian, paraovarian, or tubal) masses. We compared the diagnostic performance of these methods in a large multicenter study...
  73. ncbi The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer
    T S Barlow
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Int J Gynecol Cancer 16:496-500. 2006
    ..001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.686. We conclude that preoperative serum CA125 did not reliably predict OD in patients with stage III-IV EOC...
  74. ncbi Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
    J Kaern
    Department of Gynecologic Oncology, University of Oslo, The Norwegian Radium Hospital, Oslo, Norway
    Int J Gynecol Cancer 15:1014-22. 2005
    ..Normal CA125 level before platinum therapy and negative Ki-67 expression also predicted a more favorable prognosis...
  75. ncbi Retinoid receptor alpha and Beta expression in serous ovarian tumors
    A Daponte
    Department of Obstetrics and Gynecology, University Hospital of Larissa, Larissa, Greece
    Oncology 73:81-9. 2007
    ..002).RARbeta and ERalpha expression did not correlate with RARalpha tumor characteristics or PFS and survival...
  76. ncbi Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer
    Carla A Borgono
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Clin Cancer Res 12:1487-93. 2006
    ..001 and P = 0.014, respectively). These results indicate that hK8 is an independent marker of favorable prognosis in ovarian cancer...
  77. ncbi The value of serum bcl-2 levels in advanced epithelial ovarian cancer
    Faruk Tas
    Institute of Oncology, University of Istanbul, Istanbul, Turkey
    Med Oncol 23:213-7. 2006
    ..Also, serum bcl-2 level was a diagnostic but not a prognostic value in ovarian cancer. However, much researches still continues in this field, and exciting new knowledge will ultimately emerge...
  78. ncbi [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients]
    Li Dong
    Gynecologic Oncology Center, Peking University People s Hospital, Beijing 100044, China
    Zhonghua Fu Chan Ke Za Zhi 43:5-8. 2008
    ..To evaluate the diagnostic and prognostic value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumors...
  79. ncbi [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value]
    Xian Jie Tan
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
    Zhonghua Fu Chan Ke Za Zhi 43:9-12. 2008
    ....
  80. ncbi Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer
    Toshinari Muramatsu
    Department of Obstetrics and Gynecology, Tokai University School of Medicine, Shimokasuya 143, Isehara, Kanagawa 259 1143, Japan
    Oncol Rep 14:861-5. 2005
    ..ONCs were only detected in the lymph nodes of stage Ic patients...
  81. ncbi Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer
    J Vartiainen
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Haartmaninkatu 2, FIN-00290 Helsinki, Finland
    Int J Cancer 95:313-6. 2001
    ..The availability of this marker before surgery could facilitate selection of treatment modalities...
  82. ncbi The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis
    Liu-Ying Luo
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada
    Cancer Res 63:807-11. 2003
    ..Serum hK10 represents a novel biomarker for ovarian cancer. We conclude that preoperative serum hK10 concentration is a strong and independent unfavorable prognostic marker for ovarian cancer...
  83. ncbi Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer
    O Gemer
    Department of Obstetrics and Gynecology, Barzilai Medical Center, The Faculty of Health Sciences, Ben-Gurion University of the Negev, Ashkelon, Israel
    Acta Obstet Gynecol Scand 80:583-5. 2001
    ..CONCLUSIONS: More data are needed to determine the CA125 cut off level at which the standard approach of initial laparotomy and cytoreduction may be modified...
  84. ncbi Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer
    Narendra Pisal
    J Natl Cancer Inst 95:331; author reply 331-2. 2003
  85. ncbi Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 21:1035-43. 2003
    ..The discovery of new ovarian cancer biomarkers that are suitable for early disease diagnosis and prognosis may ultimately lead to improved patient management and outcomes...
  86. ncbi CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer
    S Memarzadeh
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UCLA School of Medicine, University of California-Los Angeles, Los Angeles, California, USA
    Int J Gynecol Cancer 13:120-4. 2003
    ..The CA125 level should not be used as a primary predictor of the outcome of cytoreductive surgery and should be viewed in the context of all other preoperative features...
  87. ncbi [Evaluation of serum sICAM-1 amd CA-125 in patients with ovarian tumors--preliminary report]
    Paweł Rzymski
    Katedry i Kliniki Zdrowia Matki i Dziecka AM w Poznaniu
    Ginekol Pol 73:1090-5. 2002
    ..The aim of our study was to evaluate concentration of soluble intracellular adhesion molecule-1 (sICAM-1) with CA-125 in ovarian cancer...
  88. ncbi Pelvic relapses in ovarian cancer. Role of CA-125, transvaginal ultrasound and color Doppler
    D Caserta
    Department of Experimental Medicine, University of L'Aquila, Italy
    Eur J Gynaecol Oncol 24:269-70. 2003
    ..0 and RI < 0.5 in all cases. US did not reveal any sign of relapse in the remaining eight patients. In all cases of pelvic relapses ultrasonic signs of recurrence preceded the increase of Ca-125 by one to six months (average 3.8)...
  89. ncbi Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses
    H M Tanir
    Department of Obstetrics and Gynecology, Osmangazi University, Eskisehir, Turkey
    Eur J Gynaecol Oncol 24:271-4. 2003
    ..902 (95% CI: 0.70-0.98) and 0.873 (95% CI: 0.66-0.91) (p = 0.14). CONCLUSION: Serum VEGF has the potential to be considered as a tumor marker with a good diagnostic relevance in differentiating the nature of ovarian masses...
  90. ncbi Leukocyte alkaline phosphatase, CA15-3, CA125, and CEA in cancer patients
    N Walach
    Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel
    Tumori 84:360-3. 1998
    ....
  91. ncbi [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion]
    Marek S Kiluk

    Pol Merkur Lekarski 13:298-301. 2002
    ..Initial observations indicate that the analysis of tumour markers CEA, CA 15-3 and CA 125 may be useful in the differential diagnosis of peritoneal effusion...
  92. ncbi Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors
    F Wakahara
    Department of Obstetrics and Gynecology, Narita Hospital, Narita, Japan
    Gynecol Obstet Invest 52:147-52. 2001
    ..If sonography is performed by an experienced gynecologic oncologist, this examination is more reliable than tumor markers. However, intraoperative frozen section should still be performed during surgery for patients with ovarian tumors...
  93. ncbi [Difficulties in differential diagnosis of adnexal masses during pregnancy: the role of greyscale and color doppler sonography]
    A Czekierdowski
    I Katedry i Kliniki Ginekologii Operacyjnej AM w Lublinie
    Ginekol Pol 72:1281-6. 2001
    ..6% (25 of 27). We conclude that although prenatal sonography has the potential to correctly classify most of adnexal masses, caution in risk assessment is needed especially when persistent solid tumor is found...
  94. ncbi Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements
    Artur Czekierdowski
    1st Department of Surgical Gynecology, Medical University of Lublin
    Ann Univ Mariae Curie Sklodowska [Med] 57:113-31. 2002
    ..VEGF serum concentration was not useful in the preoperative discrimination of malignant and benign ovarian tumors...
  95. ncbi Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum
    R L Attanoos
    Department of Histopathology, Llandough Hospital, Cardiff and Vale NHS Trust, Penarth, Vale of Glamoran, UK
    Histopathology 40:237-44. 2002
    ..The other mesothelial markers (thrombomodulin, cytokeratin 5/6, and CD44H) and carcinoma markers (polyclonal and monoclonal CEA, and Leu-M1) yielded a too low sensitivity for practical use...
  96. ncbi Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients
    Eva Sapi
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520 8040, USA
    Cancer Detect Prev 26:158-67. 2002
    ..In summary, our data demonstrated that this non-invasive blood test is sensitive and specific for detecting disseminated ovarian epithelial cells and telomerase is a potential marker for the detection of circulating ovarian tumor cells...
  97. ncbi The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer
    Claus K Høgdall
    Department of Obstetrics and Gynecology, The Gynecologic Clinic, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Denmark
    Anticancer Res 22:1765-8. 2002
    ..To study the prognostic value of pre-operative serum tetranectin (TN), CA125 levels and a mathematical formula (Index1) in primary ovarian cancer...
  98. ncbi The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer
    H Tsuda
    Department of Obstetrics and Gynecology, Osaka City General Hospital, Miyakojimahondori Miyakojima Osaka, Japan
    Int J Gynecol Cancer 12:435-7. 2002
    ..When we determine the CA125 regression rate to predict overall survival in ovarian cancer, we should take into account the kind of chemotherapy regimen, especially the use of paclitaxel...
  99. ncbi The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma
    U Saygili
    Department of Obstetrics and Gynecology, Dokuz Eylul University School of Medicine, Izmir, Turkey
    Int J Gynecol Cancer 12:438-42. 2002
    ..However, these findings need to be confirmed in more and larger studies. These results may be beneficial in the management of ovarian carcinoma patients with elevated CA125 levels...
  100. ncbi [Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factor]
    S Ivanov
    Akush Ginekol (Sofiia) 42:16-9. 2003
    ..Nevertheless this the levels of Cal25 can significantly help the oncogynaecologist in the fight against the ovarian cancer...
  101. ncbi [Cancer antigen CA 125 in ovarian cancer]
    Jarosław Debniak
    Kliniki Ginekologii AM w Gdańsku
    Ginekol Pol 74:701-9. 2003
    ..We analyzed those before primary operation (PO) and second look laparotomy (SLL). Chi 2 and t-Student tests were used...

Research Grants126 found, 100 shown here

  1. Progestogen Inhibition of Ovarian Cancer Cell Metastasis
    William Murdoch; Fiscal Year: 2003
    ....
  2. Partners Southwestern Clinical Epidemiology/Validation
    Daniel Cramer; Fiscal Year: 2007
    ....
  3. Genes, Hormones & Environment in an Ovarian Cancer Model
    Daniel Cramer; Fiscal Year: 2007
    ..Our continued goal is to identify modifiable risk factors and chemo preventive agents for a common and lethal cancer in women. ..
  4. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2007
    ..Relevance of this research to public health: By achieving early ovarian cancer diagnosis, it will be possible to reduce the burden of the disease by administration of effective treatment as early as possible. ..
  5. MUC-1 related cancer immunity: determinants and predictive significance
    Daniel Cramer; Fiscal Year: 2007
    ..The findings of our study could provide the basis for developing a safe cancer- preventing vaccine for ovarian cancer and perhaps other MUC1-expressing tumors. ..
  6. O-Glycans on Mucins at the Ocular Surface
    PABLO ARGUESO; Fiscal Year: 2007
    ..aeruginosa to the O-linked carbohydrates of individual mucins collected from tears. B. Determine in vitro how inhibition of O-glycan synthesis on membrane-associated mucins affects P. aeruginosa adherence to corneal cells. ..
  7. ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer
    Robert Bast; Fiscal Year: 2009
    ..These studies will test a novel strategy to eliminate dormant ovarian cancer cells by blocking factors required for their survival. If successful, early translation to clinical trials should be feasible. ..
  8. MUC-1 related cancer immunity: determinants and predictive significance
    Daniel Cramer; Fiscal Year: 2009
    ..The findings of our study could provide the basis for developing a safe cancer- preventing vaccine for ovarian cancer and perhaps other MUC1-expressing tumors. ..
  9. The Feasibility of Earlier Detection of Ovarian Cancer Using Symptom Reports
    Marin Andersen; Fiscal Year: 2009
    ..Outcomes of such an approach for women with and without the identified pattern of symptoms will be examined. ..
  10. Risk for New onset of Depression in Perimenopausal Women
    Daniel Cramer; Fiscal Year: 2009
    ..abstract_text> ..
  11. UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER
    Robert Bast; Fiscal Year: 2007
    ..Developmental research and career development programs have been strengthened and extended to other institutions. Perspective will continue to be provided by internal, external and advocate advisors. ..
  12. Paul Calabresi Clinical Oncology Award
    Robert Bast; Fiscal Year: 2007
    ..Each Calabresi scholar is guided by a clinical mentor and a translational mentor as well as the program's Advisory Committee, composed of experts in clinical, laboratory, and translational research. ..
  13. O-Glycans on Mucins at the Ocular Surface
    PABLO ARGUESO; Fiscal Year: 2011
    ..The understanding of the O-glycan:galectin barrier, which has not been previously described, may help in the clinical treatment of diseases in which the ocular surface is compromised. ..
  14. OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISM
    Daniel Cramer; Fiscal Year: 2002
    ..The investigators point out that only large, comprehensive epidemiologic studies capable of examining these factors within histologic subtypes are likely to succeed in identifying preventive mechanisms. ..
  15. EPIDEMIOLOGIC AND BIOLOGIC PREDICTORS OF IVF SUCCESS
    Daniel Cramer; Fiscal Year: 2002
    ....
  16. Human Kallikrein 4 (hK4): A New Prostatic Biomarker?
    Eleftherios Diamandis; Fiscal Year: 2003
    ..If successful, our research will contribute to the development of new prostatic biomarkers and possibly, to better diagnosis which may lead to better clinical outcomes and reduced healthcare costs. ..
  17. A New Biomarker for Ovarian Cancer Detection
    Eleftherios Diamandis; Fiscal Year: 2003
    ..In this grant proposal, we describe further studies, which will examine in greater detail, the ability of a test for the amount of this protein in blood to correctly diagnose the presence of ovarian cancer. ..
  18. PROTEINS IN MOLECULAR MECHANISMS OF TEAR FILM FORMATION
    BEN GLASGOW; Fiscal Year: 2009
    ....
  19. "Mucins of the Ocular Surface"
    Ilene K Gipson; Fiscal Year: 2010
    ..abstract_text> ..
  20. CELL MOTILITY AND ADHESION IN CORNEAL WOUND HEALING
    Ilene Gipson; Fiscal Year: 1980
    ..Utilizing such information will allow us to probe abnormally healing corneas to determine what cell alterations lead to persistent epithelial defects and recurrent corneal erosions...
  21. Statins & Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
    Marianne Ulcickas Yood; Fiscal Year: 2010
    ....
  22. PROTEINS IN MOLECULAR MECHANISMS OF TEAR FILM FORMATION
    Ben J Glasgow; Fiscal Year: 2010
    ....
  23. Treatment of Chemotherapy-Resistant Human Ovarian Cancer by Administration of CPE
    Alessandro Santin; Fiscal Year: 2009
    ..Results of the proposed research will lay the foundation for rapid clinical translation of an innovative, potentially highly effective treatment for patients with chemotherapy-resistant ovarian cancer. ..
  24. Treatment of Chemotherapy-Resistant Human Ovarian Cancer by Administration of CPE
    Alessandro D Santin; Fiscal Year: 2010
    ..Results of the proposed research will lay the foundation for rapid clinical translation of an innovative, potentially highly effective treatment for patients with chemotherapy-resistant ovarian cancer. ..
  25. Mesothelin as biomarker and therapeutic target
    Ingegerd Hellstrom; Fiscal Year: 2009
    ..We have recently constructed an assay to measure antibodies to mesothelin to improve diagnosis. The proposed work aims to evaluate this assay and also to develop immunotherapy targeting mesothelin. ..
  26. COLON CANCER SURVIVORS--MEDICATIONS & RISK OF RECURRENCE
    Christine Johnson; Fiscal Year: 2004
    ..Using automated pharmacy data, the timing of use and exposure to NSAIDs and HRT will be analyzed among cancer survivors, along with potentially confounding variables, in relation to these outcomes. ..
  27. OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISM
    Daniel Cramer; Fiscal Year: 1993
    ..The role of galactose rich foods in ovarian cancer etiology is particularly important because of a substantial increase in the use of these foods in the United States...
  28. MENTORING & ADVANCED RESEARCH TRAINING FOR WRHR SCHOLARS
    Jonathan Berek; Fiscal Year: 2007
    ..This cadre of Scholars will be among future leaders in women's reproductive health research in the United States. ..
  29. The role of mucin-protein interactions in the innate defense of the lung
    Mehmet Kesimer; Fiscal Year: 2010
    ....
  30. Mesothelin as biomarker and therapeutic target
    Ingegerd Hellstrom; Fiscal Year: 2009
    ..We have recently constructed an assay to measure antibodies to mesothelin to improve diagnosis. The proposed work aims to evaluate this assay and also to develop immunotherapy targeting mesothelin. ..